Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»Construction»ACROMEC Secures Contracts in Healthcare Pharma Industries Totaling S$6.2M
    Construction

    ACROMEC Secures Contracts in Healthcare Pharma Industries Totaling S$6.2M

    Marie JonesBy Marie JonesJuly 6, 2018No Comments4 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    SINGAPORE – (ACN Newswire) – ACROMEC Limited (“ACROMEC”, SGX:43F), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biomedical, research and academia sectors, has secured three new contracts totaling approximately S6.2 million.

    The first contract is for additions and alterations to a new endoscopy suite at a medical centre for a repeat customer in the healthcare industry. The project will be carried out in two phases and is expected to be completed by the end of the current financial year ending 30 September 2018 (“FY2018”). This repeat order reflects our customer’s trust in us to continue delivering quality services. The growing healthcare industry will continue to be our area of focus. Barring unforeseen circumstances, it will provide us opportunities, as this industry is supported by infrastructure spending by both the public and private sectors so as to cater to the needs of our ageing population in Singapore.

    The second contract is awarded by a multinational corporation customer in the human and environmental health sector. The Group will undertake the process engineering works and also provide furniture for its testing, showcase and research laboratory facilities. This will be a fast paced three-month project and is expected to be completed by the end of FY2018.

    In addition, a third contract has been awarded to the Group as the nominated sub-contractor for the fitting out of a cleanroom that complies with Good Manufacturing Practices standards for a biomedical company in the pharmaceutical industry. The contract is expected to be completed by the 1st quarter of the financial year ending 30 September 2019. This win is a testament that our efforts to penetrate the pharmaceutical industry has gained traction.

    With these contracts, the Group’s order book now stands at approximately S$18 million.

    These contracts are expected to contribute positively to the earnings per share and net tangible assets per share of the Group for the FY2018.

    None of the Directors of the Company has any interest, direct or indirect, in these contract, other than through their respective shareholdings in the Company. To the best of the Directors’ knowledge, none of the controlling shareholders or substantial shareholders of the Company has any interests, direct or indirect, in these contracts, other than through their respective shareholdings in the Company.

    About ACROMEC Limited (SGX:43F)

    ACROMEC is an established specialist engineering services provider with more than 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

    ACROMEC’s business is divided into two main business segments: (i) Engineering, procurement and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.

    The Group mainly serves the healthcare, biomedical, pharmaceutical, research and academia, and electronics sectors. ACROMEC counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies. For more information, please visit www.acromec.com.

    Media and Analysts Contact:

    Acromec Limited
    Mr Jerry Tan
    Chief Financial Office
    Tel: +65 6415 0574
    Email: jerry.tan@acromec.com

    Waterbrooks Consultant Pte Ltd
    Mr Ng Tian Khean
    Mobile: +65 9640 2808
    Email: tk@waterbrooks.com.sg

    This media release has been prepared by ACROMEC and its contents have been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”). The Sponsor has not independently verified the contents of this media release.

    This media release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

    The contact person for the Sponsor is Ms Alicia Sun (Telephone: +65 6532 3829) at 1 Robinson Road #21-02 AIA Tower, Singapore 048542.

    Topic: Contract Awarded
    Sectors: HealthCare, Const/Eng
    http://www.acnnewswire.com
    From the Asia Corporate News Network

    Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleThe Executive Talk: TTW PCL (SET:TTW)
    Next Article DGIP visits Japan and Korea to promote Hong Kong’s role in Guangdong-Hong Kong-Macao Bay Area

    Related Posts

    China State Construction Int’l MiC Tech Gains Momentum, Completed-Home Sales Policy in the Chinese Mainland Accelerates Industry Transformation

    September 16, 2026

    GAFA 2026 Strengthens Malaysia’s Built Environment Ecosystem Through Landmark Co-location

    September 3, 2026

    Yuanda China Advancing Steady and Long-Term Growth from Within and Beyond, 2026 Interim Revenue Surged by 23.2% Year on Year to RMB 1.56 Billion

    September 1, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production
    • Study Finds Lower Rates of Overweight Among Vegan-Fed Cats
    • Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary, Over 300 Guests Gather to Mark Glorious Milestone
    • ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease
    • MicroVision Begins Commercial Production of MOVIA(TM) Pro for Superior Short-Range Sensing and Onboard Perception, Enabling Physical AI at the Edge
    • New Global Initiative Seeks to Modernize Health Workforce Mobility
    • P&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards
    • Zhipu, Jiangmen, QuantGroup and Other Investors Join Forces to Back RMB 1 Billion Cognitive Intelligence Venture Capital Fund for Physical AI Ecosystem Development
    • Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027
    • Chervon Appoints Stephen Sarnocinski to President – End User Research, Sales and Service – OPE Commercial Landscaping Market Global
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.